Avidity Biosciences Inc [RNA] stock prices are up 1.64% to $47.82 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 7.85% over the last week, with a monthly amount glided 33.02%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Bernstein started tracking the stock with Outperform rating on June 24, 2025, and set its price target to $50. On June 17, 2025, Wolfe Research initiated with a Outperform rating and assigned a price target of $55 on the stock. Raymond James started tracking the stock assigning a Strong Buy rating and suggested a price target of $65 on June 11, 2025. Citigroup initiated its recommendation with a Buy and recommended $70 as its price target on March 13, 2025. BMO Capital Markets started tracking with a Outperform rating for this stock on March 12, 2025, and assigned it a price target of $72. In a note dated March 07, 2025, Scotiabank initiated an Sector Outperform rating and provided a target price of $70 on this stock.
The stock price of Avidity Biosciences Inc [RNA] has been fluctuating between $21.51 and $56.00 over the past year. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $47.82 at the most recent close of the market. An investor can expect a potential return of 46.38% based on the average RNA price forecast.
Analyzing the RNA fundamentals
The Avidity Biosciences Inc [NASDAQ:RNA] reported sales of 10.73M for trailing twelve months, representing a surge of 88.12%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 46.94 points at the first support level, and at 46.05 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.35, and for the 2nd resistance point, it is at 48.87.
Ratios To Look Out For
It’s worth pointing out that Avidity Biosciences Inc [NASDAQ:RNA]’s Current Ratio is 9.26. In addition, the Quick Ratio stands at 9.26 and the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 573.36, the price to book ratio is 4.84.
Transactions by insiders
Recent insider trading involved Hughes Steven George, Chief Medical Officer, that happened on Aug 22 ’25 when 2208.0 shares were sold. Chief Human Resources Officer, McCarthy Teresa completed a deal on Aug 15 ’25 to sell 10000.0 shares. Meanwhile, Officer TERESA MCCARTHY bought 45000.0 shares on Aug 15 ’25.
